CollPlant Biotechnologies today announced that researchers at Mayo Clinic have successfully developed the first fully humanized 3D bioprinted skin model using the company’s plant‑derived recombinant human collagen (rhCollagen) bioinks. The model incorporates human skin fibroblasts, melanocytes and keratinocytes, and is integrated into a skin‑on‑a‑chip system that enables evaluation of topical and transdermal drug delivery in a non‑animal setting.
The breakthrough demonstrates the versatility of CollPlant’s rhCollagen platform beyond its core regenerative medicine products. By providing a high‑throughput, personalized human skin model, the technology offers a powerful alternative to animal testing for cosmetic and pharmaceutical research, potentially accelerating drug development timelines and reducing regulatory hurdles.
CEO Yehiel Tal highlighted the significance of the achievement, noting that the model “provides a template for producing personalized human skin models at scale, enabling the reduction of animal testing, and creating learnings to apply to advancements in regenerative medicine.” The development underscores CollPlant’s expanding role in 3D bioprinting and positions the company to capture new opportunities in drug testing and regenerative therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.